Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (INMB) on March 29, 2021. The report discloses the entry into a material definitive agreement and the filing of an investor presentation slide deck.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed relates to the new advisory agreement:
- Advisory Fee: $91,666 per month.
- Contract Duration: 12 months.
- Total Contract Value: Approximately $1.1 million (based on monthly fee).
Material Changes
The primary material change reported is the execution of a financial advisory agreement with National Securities Corporation ("National") on March 29, 2021. Under this non-exclusive agreement, National will provide services including:
- Organization of "non-deal" roadshows for retail and institutional investors.
- Access to National's Biotechnology Research Analyst for strategy discussions.
- Assistance with investor relations strategies and the preparation of investor kits and presentations.
The stated goal is to increase name recognition and familiarity with the Company's business model and activities.
Guidance, Outlook, and Risks
The filing includes an investor presentation (Exhibit 99.1) intended for use in company presentations. Management explicitly states that the information in the presentation is summary in nature and should be considered in the context of other SEC filings and public announcements. The Company undertakes no obligation to update or revise the information contained in this report, though it may do so at management's discretion. No specific financial guidance or forward-looking projections are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the total cash impact of the $91,666 monthly advisory fee against the Company's current cash reserves.
- Review the attached Exhibit 99.1 (Investor Presentation) for specific strategic updates not detailed in the 8-K text.
- Confirm the Company's status as an "Emerging Growth Company" and any associated reporting exemptions.
- Monitor future filings for updates on the effectiveness of the "non-deal" roadshows and investor relations activities.